X4 Pharmaceuticals (NASDAQ:XFOR) Price Target Increased to $

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) had its target price lifted by equities researchers at HC Wainwright from $3.00 to $5.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 352.49% from the company’s […]

Related Keywords

Paula Ragan , Adams Mostafa , Securities Exchange Commission , Pharmaceuticals Stock Performance , Capital Partners , Pharmaceuticals Company Profile , Pharmaceuticals Daily , Stonepine Capital Management , Pharmaceuticals Inc , Bain Capital Life Sciences Investors , Sg Americas Securities , Get Free Report , Exchange Commission , Capital Life Sciences Investors , Capital Management , X4 Pharmaceuticals , Nasdaq Xfor , Wexfor , Medical , Boost Price Target , Hc Wainwright ,